Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

BlueWind Medical Appoints Dr. Roger R. Dmochowski, MD, MMHC, as Chief Medical Officer

BlueWind Medical
Posted on: 30 Jul 18
BlueWind Medical Appoints Dr. Roger R. Dmochowski, MD, MMHC, as Chief Medical Officer

PR Newswire

HERZLIYA, Israel, July 30, 2018

HERZLIYA, Israel, July 30, 2018 /PRNewswire/ --

BlueWind Medical, a developer of a miniature, wireless neurostimulation platform for the treatment of multiple clinical indications, announced today the appointment of Dr. Roger R. Dmochowski of Vanderbilt University as the company's chief medical officer (CMO). Dr. Dmochowski will be leading clinical efforts, including the upcoming OASIS (OverActive bladder StImulation System study) pivotal trial of RENOVA iStim™ for the management of overactive bladder (OAB). The study is expected to commence in early 2019, with an overall target of 250 patients to be implanted with RENOVA iStim™ in up to 25 medical centres in several European countries.

Dr. Dmochowski is a world-renowned leader in the fields of urology, OAB and incontinence, a recipient of the Zimskind Award and Lifetime Achievement Awards from the Urodynamics Society for his accomplishments in the clinical treatment for incontinence, a Fellow of the American College of Surgeons, a member of the American Urological Association and International Continence Society, and a trustee of the American Board of Urology. An accomplished scholar, Dr. Dmochowski has published over 320 articles, 100 book chapters and 460 abstracts, given over 260 presentations at various national and international meetings, led and participated in dozens of OAB and incontinence studies, is the Editor-in-Chief of NeuroUrology and Urodynamics, and serves on the editorial board for several scientific journals. Dr. Dmochowski will continue to serve in clinical and academic roles with the Vanderbilt university as well as other medical association positions.

"I am extremely pleased to be able to provide medical oversight to the clinical trial of the RENOVA iStim™, which I believe will have a significant positive impact on patients' lives," said Dr. Dmochowski.

"We are delighted to formally welcome Dr. Dmochowski to our team, and we are certain he will add great value to BlueWind through his knowledge, experience and enthusiasm," commented Guri Oron, BlueWind's CEO.

About BlueWind Medical 

BlueWind Medical was founded in 2010 by Rainbow Medical. The company is developing a platform technology of miniature, wireless, neurostimulators that can be injected or implanted in a minimally invasive procedure to treat multiple indications. By putting patients' needs first, BlueWind Medical's team of experienced and dedicated engineers and researchers are creating a versatile and effective platform that will transform neuromodulation as we know it.

About Rainbow Medical 

Rainbow Medical (http://www.rainbowmd.com ) is a unique private operational investment company that seeds and grows start-up companies developing breakthrough medical devices, addressing significant unmet market needs in a diverse range of medical fields.

For more information, contact:
Ms. Meital Levi Tal, meital@xmind.co.il

SOURCE BlueWind Medical

PR Newswire
www.prnewswire.com

Last updated on: 30/07/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.